Nivolumab/Ipilimumab Bests Nivolumab in Ovarian and Extra-Renal Clear Cell Carcinomas
Nivolumab (Opdivo) plus ipilimumab (Yervoy) elicited higher response rates vs nivolumab monotherapy and improved outcomes for patients with ovarian or other extra-renal clear cell carcinomas, according to data presented at the 2024 ASCO Annual Meeting. …